All News
Filter News
Found 808,963 articles
-
Halozyme Therapeutics, Inc. Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
10/19/2011
-
GlaxoSmithKline May Make $4.8 Billion Bid for Human Genome Sciences, Inc.: Source
10/19/2011
-
Blood Type May Affect Survival After Heart Bypass, Duke University Medical Center Study
10/19/2011
-
Forgetting is Part of Remembering, University of Illinois Study
10/19/2011
-
AstraZeneca PLC and Forest Laboratories, Inc. Put Superbug Drug into Late-Stage Trials; Eyes 2014 Regulatory Filing
10/19/2011
-
Could Hypertension Drugs Help People With Alzheimer's? University of Bristol Study
10/19/2011
-
Allozyne, Inc. Announces Positive Results from Phase 1B Trial of AZ01
10/19/2011
-
Healthier Diet, Stronger Sperm? Harvard School of Public Health Study
10/19/2011
-
Surprising Link Between Bacteria and Colon Cancer, BC Cancer Agency Study
10/19/2011
-
Teva Pharmaceutical Industries Limited Parkinson's Drug Doesn't Slow Disease
10/19/2011
-
Shift Work in Teens Linked to Increased Multiple Sclerosis Risk, Karolinska Institute Study
10/19/2011
-
Vertex Pharmaceuticals Incorporated Submits Application for Priority Review and Approval of KALYDECO(TM) (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis
10/19/2011
-
Protein That Fuels Lethal Breast Cancer Growth Emerges as Potential New Drug Target, Duke Cancer Institute Study
10/19/2011
-
When Shyness is the Sign of Something More, National Institute of Mental Health Study
10/19/2011
-
Omega-3 Fatty Acids Shown to Prevent or Slow Progression of Osteoarthritis, University of Bristol Study
10/19/2011
-
Oxford University Study Finds Link Between Swine Flu and Stillbirth
10/19/2011
-
BioMimetic Therapeutics, Inc. Receives Approval to Commercialize Augment® Bone Graft in Australia
10/19/2011
-
STAAR Surgical Company Reports Progress on Japan Application for Approval of Visian Toric Implantable Collamer(R) Lens (TICL)
10/19/2011
-
Presbia’s Flexivue Microlens® Receives Approval for Patient Implantation in Brazil
10/19/2011
-
Amicus Therapeutics, Inc. Announces Close of Patient Recruitment in First Phase 3 Study of Amigal(TM) for Fabry Disease
10/19/2011